Illumina Inc Dossier
Qualitative Analysis
Business overview
Illumina, Inc. is a global leader in DNA sequencing and array-based technologies, serving customers in life sciences, oncology, reproductive health, genetic disease, agriculture, and microbiology. The company generates over 90% of its revenue from sequencing instruments, consumables, and services, with high-throughput platforms like the NovaSeq X driving large-scale genomic projects. Following the strategic spin-off of GRAIL in June 2024, Illumina has refocused on its core sequencing business and high-margin consumables.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Migrating high-throughput sequencing customers from legacy platforms (such as NovaSeq 6000) to the flagship NovaSeq X and NovaSeq X Plus systems, powered by XLEAP-SBS chemistry.
Expected impact: Lowers the cost per genome toward the $200 target, driving higher consumables utilization and expanding recurring revenue streams.
Integrating proteomics and single-cell capabilities directly into Illumina's next-generation sequencing (NGS) ecosystem, utilizing technologies from the SomaLogic and Fluent BioSciences acquisitions.
Expected impact: Enables customers to generate comprehensive multiomic datasets at scale, expanding Illumina's addressable market beyond genomics into proteomics and single-cell analysis.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To deeply expand Illumina's leadership in the proteomics and multiomics markets by combining SomaLogic's SomaScan technology with Illumina's NGS ecosystem, DRAGEN software, and Connected Multiomics platform.
Financial impact: Expected to contribute 1.5% to 2.0% of revenue growth in fiscal year 2026, with an EPS dilution of approximately $0.18. Projected to become profitable on a non-GAAP operating income basis in 2027.
To acquire highly differentiated single-cell analysis technology (PIPseq V) that eliminates the need for complex, expensive instrumentation, making single-cell analysis accessible to a broader customer base.
Financial impact: Funded with cash on hand; expands capabilities in life science tools to drive long-term consumables growth.
Strategic Partnerships
Supports MyOme's Proactive Health (MPH) Trial and the expansion of its proactive health and rare disease diagnostic tests, combining Illumina's sequencing technology with MyOme's AI-integrated risk models.
Terms: Illumina made a strategic investment of an undisclosed amount in MyOme's latest financing round.
Focuses on developing distributed in vitro diagnostic (IVD) test offerings for comprehensive genomic profiling (CGP) and whole-genome sequencing (WGS), and co-commercializing complementary liquid and tissue biopsy assays.
Terms: Terms of the expanded collaboration were not publicly disclosed.